Thus, RhoA inactivation by simvastatin treatment might have led to the reduced migration of ccRCC cells in the transwell assay, which was confirmed in DNRhoA, but not CARhoA, cells. This evidence concerns the gene RHOA and nonpapillary renal cell carcinoma.